BioAtla, Inc.
BCAB- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001826892
No open-market purchases or sales by BioAtla, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.22M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding BioAtla, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 80 | 73 | −7 |
| Shares | 23.5M | 24.9M | +1.37M (+5.8%) |
| Value | $67.1M | $191.5M | +$124.4M (+185.4%) |
New holders (19)
Institutions that held BioAtla, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Eventide Asset Management, LLC | 795,000 | $6.12M | 0.12% |
| Point72 Asset Management, L.P. | 764,700 | $5.89M | 0.03% |
| Avoro Capital Advisors LLC | 575,000 | $4.43M | 0.08% |
| Altium Capital Management LP | 553,000 | $4.26M | 1.60% |
| Acuta Capital Partners, LLC | 520,000 | $4.00M | 1.78% |
| Silverarc Capital Management, LLC | 200,422 | $1.54M | 0.65% |
| UBS Oconnor LLC | 112,000 | $862.0K | 0.01% |
| Susquehanna Fundamental Investments, LLC | 107,796 | $830.0K | 0.01% |
| Fred Alger Management, LLC | 41,171 | $317.0K | 0.00% |
| Dimensional Fund Advisors LP | 26,861 | $207.0K | 0.00% |
| Bridgeway Capital Management, LLC | 22,000 | $169.0K | 0.00% |
| BNP Paribas Arbitrage, SA | 16,279 | $125.3K | 0.00% |
| Bank of New York Mellon Corp | 13,150 | $101.0K | 0.00% |
| DekaBank Deutsche Girozentrale | 12,500 | $95.0K | 0.00% |
| Denali Advisors LLC | 7,300 | $56.0K | 0.03% |
| UBS Group AG | 5,584 | $43.0K | 0.00% |
| Point72 Hong Kong Ltd | 421 | $3.00K | 0.00% |
| China Universal Asset Management Co., Ltd. | 340 | $3.00K | 0.00% |
| Cutler Group LP | 105 | $0 | 0.00% |
Sold out (26)
Institutions that held BioAtla, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.